Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus PT from Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have received a consensus rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $3.67.

A number of brokerages recently weighed in on LXRX. Piper Sandler reduced their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Friday. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Leerink Partners restated a “market perform” rating and set a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Leerink Partnrs lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX opened at $0.39 on Friday. The stock has a market capitalization of $96.48 million, a PE ratio of -0.52 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The business has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $1.13. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.83.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The firm had revenue of $26.55 million during the quarter, compared to analysts’ expectations of $6.48 million. As a group, equities analysts predict that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of LXRX. FMR LLC grew its holdings in Lexicon Pharmaceuticals by 28.9% during the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock valued at $78,291,000 after purchasing an additional 11,179,919 shares during the period. Point72 Asset Management L.P. grew its holdings in Lexicon Pharmaceuticals by 630.7% during the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company’s stock valued at $6,638,000 after purchasing an additional 7,758,371 shares during the period. Schonfeld Strategic Advisors LLC grew its holdings in Lexicon Pharmaceuticals by 301.5% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company’s stock valued at $5,582,000 after purchasing an additional 5,676,021 shares during the period. Nantahala Capital Management LLC grew its holdings in Lexicon Pharmaceuticals by 186.6% during the fourth quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company’s stock valued at $4,877,000 after purchasing an additional 4,300,000 shares during the period. Finally, Tang Capital Management LLC lifted its position in shares of Lexicon Pharmaceuticals by 750.3% during the fourth quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company’s stock worth $628,000 after acquiring an additional 750,268 shares in the last quarter. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.